DOI: 10.12890/2025_005463

Nephrogenic diabetes insipidus associated with temozolomide therapy in a patient with grade IV astrocytoma

Authors

  • Zayd Fargouche Department of Internal Medicine, Hôpital Universitaire de Bruxelles (H.U.B.), Université Libre de Bruxelles (ULB), Brussels, Belgium
  • Martin Manderlier Department of Radiotherapy, Hôpital Universitaire de Bruxelles (H.U.B.), Université Libre de Bruxelles (ULB), Brussels, Belgium
  • Anne-Pascale Meert Department of Internal Medicine, Hôpital Universitaire de Bruxelles (H.U.B.), Université Libre de Bruxelles (ULB), Brussels, Belgium
  • Louis Wolff Department of Internal Medicine, Hôpital Universitaire de Bruxelles (H.U.B.), Université Libre de Bruxelles (ULB), Brussels, Belgium
  • Maxime Ilzkovitz Department of Internal Medicine, Hôpital Universitaire de Bruxelles (H.U.B.), Université Libre de Bruxelles (ULB), Brussels, Belgium

zayd.fargouche@ulb.be

Keywords

Nephrogenic diabetes insipidus, Temozolomide, Tubulointerstitial nephritis

Abstract

Temozolomide (TMZ), an alkylating agent used in glioblastoma multiforme and anaplastic astrocytoma treatment, is generally associated with side effects like myelosuppression and nausea. This case report describes a rare occurrence of nephrogenic diabetes insipidus (NDI) in a 45-year-old male with grade IV astrocytoma undergoing TMZ therapy. Following TMZ discontinuation due to haematological toxicity, the patient developed significant polyuria and hypernatremia. Central diabetes insipidus was initially suspected, but limited improvement with desmopressin and normal endocrine investigations suggested renal involvement. The diagnosis of partial NDI was made and linked to TMZ-induced acute tubulointerstitial nephropathy (ATN). Despite symptom onset coinciding with TMZ administration, recovery was delayed after discontinuation, implicating possible lasting tubular damage. Although the precise pathogenesis remains uncertain, it may involve TMZ-induced renal tubule inflammation, affecting aquaporin-2 expression and water retention. In this case, management of NDI included adequate intravenous hydration, oral fluid restriction, and progressive resolution of polyuria without the need for diuretic or non-steroidal anti-inflammatory drug. This case emphasizes the need for vigilance regarding renal complications, particularly NDI, in patients receiving TMZ, warranting careful monitoring of electrolytes, renal function and diuresis to ensure prompt identification and management of this rare but serious side effect.

View the entire article

Downloads

References

  1. Christ-Crain M, Bichet DG, Fenske WK, Goldman MB, Rittig S, Verbalis JG et al. Diabetes insipidus. Nat Rev Dis Primers 2019;5:54. doi: 10.1038/s41572-019-0103-2
  2. Bockenhauer D, Bichet DG. Pathophysiology, diagnosis and management of nephrogenic diabetes insipidus. Nat Rev Nephrol 2015;11:576-588. doi: 10.1038/nrneph.2015.89
  3. Athavale A, Morris J, Jardine M, Gallagher M, Sen S, Ritchie A, et al. Acute interstitial nephritis and nephrogenic diabetes insipidus following treatment with sulfamethoxazole-trimethoprim and temozolomide. Nephrology 2021;26:12-14. doi: 10.1111/nep.13783
  4. Mahiat C, Capes A, Duprez T, Whenham N, Duck L, Labriola L. Central diabetes insipidus induced by temozolomide: A report of two cases. J Oncol Pharm Pract 2021;27:1040–1045. doi: 10.1177/1078155220961551
  5. Moll T, Lott D, Wright V, Lien L, Subauste J. PMON89 Nephrogenic Diabetes Insipidus in a Patient on Temozolomide. J Endocr Soc 2022;6:A569. doi: 10.1210/jendso/bvac150.1181
  6. Vakilian S, Thébaut J, Ruo R, Marcovitz S, Panet-Raymond V, Shenouda G et al. Examination of the Dose-Effect Relationship of Radiation-Induced Hypopituitarism: Results of a Case-Control Study. Adv Radiat Oncol 2021;6:100693. doi: 10.1016/j.adro.2021.100693
  7. Noël G, Antoni D, Barillot I, Chauvet B. Délinéation des organes à risque et contraintes dosimétriques [Delineation of organs at risk and dose constraints]. Cancer Radiother 2016;20:S36-60. French. doi: 10.1016/j.canrad.2016.07.032
  8. Shirali AC, Perazella MA. Tubulointerstitial injury associated with chemotherapeutic agents. Adv Chronic Kidney Dis 2014;21:56-63. doi: 10.1053/j.ackd.2013.06.010
  9. Singer I, Forrest JN. Drug-induced states of nephrogenic diabetes insipidus. Kidney Int 1976;10:82–95. doi: 10.1038/ki.1976.80

Published

2025-05-27

How to Cite

1.
Fargouche Z, Manderlier M, Meert A-P, Wolff L, Ilzkovitz M. Nephrogenic diabetes insipidus associated with temozolomide therapy in a patient with grade IV astrocytoma. EJCRIM [Internet]. 2025 May 27 [cited 2026 Nov. 18];12(6). Available from: https://ojs.wedare.app/ejcrim/article/view/5463

Most read articles by the same author(s)